International Data Suggests Estrogen May Play Key Role in Defying Peritoneal Mesothelioma

Mesothelioma Law Firm Baron and Budd Joins ADAO in Prompting Cutting-Edge Medical Research

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

DALLAS (PRWEB) March 26, 2013

In New South Wales, Australia, a possible mesothelioma breakthrough is emerging: Early tests show that a form of estrogen— the sex hormone estradiol— may slow down or speed up peritoneal mesothelioma growth depending on its location and proximity to estrogen receptors (ERs). “Peritoneal” means the abdominal lining. This kind of mesothelioma accounts for 20-30 percent of all mesothelioma diagnoses (http://www.survivingmesothelioma.com/news/view.asp?ID=001459#.UU9Qcr81ZSU).

Estradiol is the most important form of estrogen, produced in female ovaries and adrenal glands but also contained at much lower levels in male testosterone. The trick is whether estradiol settles inside the nucleus of the cell where it binds with protein groups called estrogen receptors (ERs) for healthy gene function, or whether it floats outside the nucleus settling in a jelly-like membrane that separates the cell nucleus from the cell wall. In the first case, mesothelioma cells appear to halt; in the second case they appear to run wild.

New South Wales scientists measured ER levels in 42 patients with peritoneal mesothelioma. Thirty-three patients showed the presence of estradiol (ER) in the nucleus of their cells, where healthy gene signals are processed. The other nine patients showed the presence of ER-â outside the nucleus in the jelly-like wall. When outcomes were compared mesothelioma cells seemed to flourish when the hormone was missing inside the nucleus, but present outside in the wall. The study will be repeated on a larger scale in hopes of adding this data to clinical mesothelioma treatment.

At the University of Fresh South Wales, cancer specialists reported the case of a 48-year-old woman who is alive and cancer-free eight years from the day she was diagnosed with peritoneal mesothelioma. Her extended survival is attributed to a combination of factors such as age and disease advancement— but most noticeably to high levels of estradiol interacting with ERs inside the peritoneal tumor. When measured, the patient’s blood estradiol levels were found equal to that of a woman at the peak stage of the ovarian cycle. Peritoneal tumors are very aggressive, but in this case the tumor was suppressed
(http://healthmad.com/conditions-and-diseases/australian-mesothelioma-survivor-disease-free-seven-years-after-diagnosis/).

Meanwhile a study authored by an Italian research team (Public Library of Science) found that the presence of estrogen and estrogen receptors may facilitate a better response to the mesothelioma chemotherapy drug Gefitinib, while also helping doctors select which patients are most likely to respond positively (http://www.wiredprnews.com/2010/12/31/mesotheliomaweborg-new-method-found-to-determine-chemotherapy-effects_2010123115991.html).

Statistics show that often women suffering from mesothelioma have less aggressive tumors and survive longer than men, all other factors being equal. Researchers are finding that the more estrogen mesothelioma cells contain, the less the cancer cells grew. The need for more studies regarding the therapeutic use of estrogen in mesothelioma patients is merited.

Last weekend saw the wrap of the Asbestos Disease Awareness Organization (ADAO)’s Ninth Annual Asbestos Awareness Conference. The conference offered a platform for broad discussion about gene therapy and new cellular treatments for defeating mesothelioma. National mesothelioma law firm Baron and Budd proudly supports ADAO and joins in the call not only for urgent research but a global asbestos ban. More than 50 nations have passed a ban. The United States has not— despite the Senate’s unanimous vote this year to observe “National Asbestos Week” for the ninth year running (April 1-7). Together with Baron and Budd, ADAO commends Senator Max Baucus (D-MT) for his congressional leadership in passing the resolution unanimously.

If your life is shadowed by a mesothelioma diagnosis, find options at http://www.mesotheliomanews.com. Mesothelioma News is sponsored by Baron and Budd to serve all those affected by mesothelioma exposure.

About Baron & Budd

The national mesothelioma law firm of Baron & Budd, P.C. has a more than 30-year history of “Protecting What’s Right” for asbestos sufferers and their families. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exposure to asbestos. Baron & Budd achieved the largest mesothelioma verdict ever in the state of Texas, a $55 million verdict for an asbestos sufferer and his family in El Paso, Texas. Contact Baron and Budd at 1.866.855.1229 for additional information on mesothelioma treatments, mesothelioma cancer doctors and treatment centers and mesothelioma attorneys.


Contact

  • Amanda Theaker, Marketing
    Baron & Budd
    214.991.1051
    Email